Boston, MA 06\/16\/2014 (wallstreetpr) \u2013\u00a0<\/b>Medical technology company, Boston Scientific corporation (NYSE:BSX)<\/b> disclosed that the treatment given to Parkinson disease patients with its Vercise Deep Brain stimulation or DBS process displayed a consistent and significant improvement in motor scores during the one-year results of the vantage clinical trial evaluation.<\/p>\n
Favorable Results<\/b><\/p>\n
The company presented the data at the 18th<\/sup> International Congress of Parkinson\u2019s Disease and Movement Disorders. The company indicated that its study of vantage indicated a 62% improvement in motor function in one year after implant. It was assessed using the UPDRS III scale in comparison with baseline. The result is in consistent with the interim data of six month period presented last year that illustrated patients\u2019 benefits from the treatment over time.<\/p>\n The significant point of the benefits that the patients received was that its medication usage was cut by 58% at one year time compared to the usage before the DBS system. Boston Scientific Corporation (NYSE:BSX)\u00a0said that Vantage is a probable, multi-center experimentation assessing the vercise DBS process evaluating the outcome of patient in Parkinson diseases, including safety, heath economic data, and effectiveness.<\/p>\n Life Time of Battery<\/b><\/p>\n Boston Scientific Corporation (NYSE:BSX)\u00a0indicated that 48 patients, who had Parkinson diseases, were treated with Vercise DBS process at six European centers. The data also suggested that the overall quality of motor function\u2019s life for the Vantage trial patients had indicated significant improvement. During the next five years, the medical technology company is planning to follow these Vantage trial patients since the Vercise DBS process is the only rechargeable one with 25 years of battery life.\u00a0 As a result, there is no need for any patient to undergo replacement surgery for battery every few years and can look for gains from their treatment over time.<\/p>\n President Speaks Boston, MA 06\/16\/2014 (wallstreetpr) \u2013\u00a0Medical technology company, Boston Scientific corporation (NYSE:BSX) disclosed that the treatment given to Parkinson disease patients with its Vercise Deep Brain […]<\/p>\n","protected":false},"author":3,"featured_media":23303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2960,1020],"stock_ticker":[],"class_list":["post-25875","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-boston-scientific-corporation-nysebsx","tag-nysebsx","entry"],"acf":[],"yoast_head":"\n
\n<\/b>Boston Scientific Corporation (NYSE:BSX)\u00a0president Maulik Nanavaty said that the latest one year data reinforced its faith on its Vercise DBS technology. He added that the company is fully committed to illustrating clinical value of its distinguished innovations. DBS is nothing but surgical treatment meant to cut down some symptoms of Parkinson diseases by placing the device to stimulate particular brain areas through electrical signals.<\/p>\n","protected":false},"excerpt":{"rendered":"